Product information and disease descriptionProduct descriptionProduct information
Co-prescribed/Concomitant therapies
1 evidence topic · 1 source
Zanzalintinib (XL092)
Metastatic colorectal cancer
- Manufacturer
- Exelixis
- Regulatory submission
- NDA submitted December 2025
- Launch
- Not announced
- Last updated